Eli Lilly and Company (NYSE:LLY) is considered one of the most profitable healthcare stocks to buy, with analysts setting a price target of $1,182, reflecting an 11% upside potential. The company is focused on global expansion, diabetes growth, and capitalizing on the oral medication opportunity.

Bernstein believes that Eli Lilly and Company’s beyond-incretin pipeline will show growth potential by 2026, making it the top stock pick in the sector. The firm sees 2026 as a year for potential upside surprises and highlights the company’s strong foundations for future growth.

Founded in 1876, Indiana-based Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals globally to improve people’s lives. The company is committed to making a positive impact on healthcare worldwide.

While Eli Lilly (LLY) shows investment potential, certain AI stocks may offer greater upside potential and less downside risk. Investors interested in undervalued AI stocks can explore opportunities in our free report on the best short-term AI stock.

Read more at Yahoo Finance: Eli Lilly and Company (LLY) Earns Fresh Bullish Calls from Analysts